Analysts on Wall Street are predicting that Merck (MRK) will report solid quarterly earnings and revenue growth in its upcoming release. According to the consensus estimates, the company is expected to post earnings per share (EPS) of $2.01, marking a significant increase of 43.6% compared to the same period last year. Revenue is projected to reach $15.34 billion, reflecting a 5.9% growth year-over-year. Notably, the consensus EPS estimate has been revised upward by 7% over the past 30 days, indicating analysts’ increasing confidence in the company’s performance. Beyond the headline numbers, analysts have also provided projections for specific key metrics that offer valuable insights into Merck’s business dynamics. For instance, analysts estimate “Sales- Oncology- Alliance revenue- Reblozyl” to reach $68.77 million, representing a 59.9% increase from the prior-year quarter. “Sales- Vaccines- Pneumovax” is projected to come in at $70.63 million, indicating a 26.4% decline year-over-year. Additionally, analysts forecast “Sales- Vaccines- ProQuar/M-M-R II/Varivax” to reach $544.16 million, suggesting a modest 3.1% increase compared to the same quarter last year. Furthermore, analysts estimate “Sales- Alliance revenue- Lenvima” to reach $265.43 million, representing a 14.4% year-over-year growth. “Sales- Hospital Acute Care- Bridion – U.S.” is projected to reach $301.76 million, indicating a 9.3% increase from the prior-year quarter. Analysts also expect “Product sales- Other revenues – International” to reach $198.07 million, marking a 7.5% decline year-over-year. “Sales- Oncology- Keytruda – U.S.” is estimated to reach $4.12 billion, representing an 18.2% increase from the year-ago quarter. In addition, analysts project “Sales- Hospital Acute Care- Bridion – International” to reach $124.70 million, indicating a 40.6% year-over-year decline. “Sales- Animal health – International” is estimated to reach $1.05 billion, representing a 4.2% increase from the prior-year quarter. Furthermore, analysts forecast “Sales- Animal health – U.S.” to reach $495.47 million, suggesting a 2.8% year-over-year increase. Finally, analysts project “Sales- Vaccines- Pneumovax – International” to reach $42.22 million, indicating a 24.6% decline from the year-ago quarter, and “Sales- Vaccines- Pneumovax – U.S.” to reach $28.41 million, suggesting a 29% decline from the same period last year.
Wall Street Analysts Forecast Solid Quarterly Results for Merck (MRK)
